SPOTLIGHT: Brain cancer vaccine doubles survival time
An experimental brain cancer vaccine more than doubled the survival time of patients suffering from glioblastoma multiforme. Early-stage data demonstrated that patients lived almost three years after taking the vaccine for a disease that typically kills people after one year. Report
More stories about glioblastoma
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
More Research Reports >>
SHARE
WITH: